Indegene Limited IPO
Indegene Limited was a mainboard IPO in the Healthcare Research Analytics & Technology sector, offered at ₹430–₹452 per share to raise ₹1,842 crore. The issue was subscribed 69.91× overall (QIBs 197.55×, NIIs 55.07×, retail 7.95×). It listed on 13 May 2024 at ₹655 and closed its first day at ₹571, a listing gain of +26.3% versus the ₹452 issue price. It now trades around ₹587 (+29.8% versus the issue price).
Frequently asked questions
- How many times was the Indegene Limited IPO subscribed?
- The Indegene Limited IPO was subscribed 69.91× overall — 197.55× in the QIB category, 55.07× among non-institutional investors, 7.95× in retail.
- What were the Indegene Limited IPO listing gains?
- Indegene Limited listed on 13 May 2024 at ₹655, closing its first day at ₹571 — a listing gain of +26.3% versus the ₹452 issue price.
- What were the retail allotment odds for the Indegene Limited IPO?
- Retail was subscribed 7.95×, so a single-lot application had roughly a 12.6% chance of allotment (about 1 in 8), and allotment was finalised on 9 May 2024.
- What was the price band and lot size of the Indegene Limited IPO?
- The price band was ₹430–₹452 per share, with a minimum lot of 33 shares (₹14,916 at the upper band).
- Who were the registrar and lead manager for the Indegene Limited IPO?
- Link Intime India Private Limited was the registrar, and Kotak Mahindra Capital was the book-running lead manager.